Raffi Asadorian
2020 - AcelRx Pharmaceuticals
In 2020, Raffi Asadorian earned a total compensation of $890.7K as Chief Financial Officer at AcelRx Pharmaceuticals, a 12% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $150,055 |
---|---|
Option Awards | $168,111 |
Salary | $442,900 |
Stock Awards | $118,250 |
Other | $11,400 |
Total | $890,716 |
Asadorian received $442.9K in salary, accounting for 50% of the total pay in 2020.
Asadorian also received $150.1K in non-equity incentive plan, $168.1K in option awards, $118.3K in stock awards and $11.4K in other compensation.
Rankings
In 2020, Raffi Asadorian's compensation ranked 9,091st out of 13,090 executives tracked by ExecPay. In other words, Asadorian earned more than 30.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,091 | 31st |
Manufacturing | 3,884 | 31st |
Chemicals And Allied Products | 1,572 | 30th |
Drugs | 1,375 | 30th |
Pharmaceutical Preparations | 1,016 | 30th |
Asadorian's colleagues
We found two more compensation records of executives who worked with Raffi Asadorian at AcelRx Pharmaceuticals in 2020.
News
AcelRx Pharmaceuticals CEO Vincent Angotti's 2023 pay slips 7% to $1.2M
April 29, 2024
AcelRx Pharmaceuticals CEO Vincent Angotti's 2022 pay falls 47% to $1.3M
August 28, 2023
AcelRx Pharmaceuticals CEO Vincent Angotti's 2021 pay jumps 39% to $2.4M
June 3, 2022
AcelRx Pharmaceuticals CEO Vincent Angotti's 2019 pay jumps 22% to $2.1M
April 24, 2020
AcelRx Pharmaceuticals CEO Vincent Angotti's 2018 pay falls 26% to $1.7M
May 14, 2019